Prieto Pérez, RocíoLlamas Velasco, MarMuñoz Aceituno, EsterReolid, AlejandraSaiz Rodríguez, MiriamBelmonte, CarmenRomán, ManuelOchoa Mazarro, DoloresTalegón, MaríaCabaleiro, TeresaDaudén, EstebanAbad-Santos, FranciscoOvejero Benito, María del Carmen2024-05-102024-05-102017-12-01Ovejero-Benito MC, Prieto-Pérez R, Llamas-Velasco M, Muñoz-Aceituno E, Reolid A, Saiz-Rodríguez M, Belmonte C, Román M, Ochoa D, Talegón M, Cabaleiro T, Daudén E, Abad-Santos F. Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis. Pharmacogenomics. 2018 Jan;19(1):7-16. doi: 10.2217/pgs-2017-01431744-8042http://hdl.handle.net/10637/15772Versión en abierto siguiendo la política de la revistaAims-. This study evaluated the influence of pharmacogenetics in psoriatic patients treated with adalimumab and/or infliximab. Materials and methods-. Prospective observational study evaluating the association of 124 polymorphisms with the response to adalimumab or infliximab (PASI75) in patients with moderate-to-severe plaque psoriasis at 3 months (N=95) and 6 months of treatment (N=90). Significant SNPs for univariate analysis were subjected to multivariate analysis. Results/Conclusions-. Five SNPs were associated with PASI75 at 3 months: rs6661932 (IVL), rs2546890 (IL12B), rs2145623 (NFKBIA), rs9304742 (ZNF816A) and rs645544 (SLC9A8). Furthermore, rs1061624 (TNFR1B) was associated with PASI75 at 6 months. Nevertheless, these biomarkers should be validated in large-scale studies before implementation in clinical practice.application/pdfenopen accessPsoriatic patientsPharmacogeneticsArtículo10.2217/pgs-2017-0143https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es